MBF Therapeutics (MBFT), a veterinary oncology company, is advancing the quality of cancer care for companion animals with innovative and humane therapies for the treatment of dogs and cats with cancer. Our product development portfolio includes targeted immunotherapies and small molecule drugs that specifically disrupt tumor cell metabolism and stimulate potent, systemic immune responses without affecting normal, healthy cells and organs.
advancing the quality of cancer care for companion animals
The availability of effective cancer treatments is one of the most significant unmet needs in veterinary medicine today. With an estimated 40% of companion pets in the U.S. over the age of 6 years, dogs and cats are increasingly susceptible to a variety of age-related diseases. It has been estimated that nearly half of all pets over the age of 10 will develop cancer (www.brakkeconsulting.com).
Despite recent advances, including a therapeutics adapted from human medicine, the primary cancer treatment options for dogs and cats are surgery, radiation, and chemotherapy. These palliative measures offer only a nominal extension of life, often with a significant degradation of overall quality of life for pets and their owners.
MBFT’s state-of-the-art oncology products are intended to meet the growing demand for effective cancer treatments that address not only symptoms but also the underlying disease to bring patients into long-lasting remission that will extend and maintain good quality of life. Man’s Best Friends Therapeutics is a development-stage veterinary biotechnology company with products in preclinical and early-stage clinical testing. Additional information about the company is available for investors, veterinary professionals, and pet owners.